« Return to News | R&D Trends

Aragen Bioscience, Innovent Biologics collaborate on biotherapeutic product development

Wednesday, April 3, 2013 01:46 PM

Aragen Bioscience, a privately held CRO, and Innovent Biologics, a privately held biopharmaceutical company, have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Aragen Bioscience will develop robust CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics. 

“Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products,” said Michael Yu, CEO of Innovent. 

Aragen Bioscience focuses on customer service and technical leadership to enable clients to cost-effectively accelerate their research efforts. Aragen Bioscience offers cell line development, protein expression and purification, molecular biology, cell biology immunology and diverse in vivo services to the biotech and pharmaceutical industries.  

“Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration,” said Oren Beske, Ph.D., vice president of Aragen Bioscience.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.